ArticleFrontiers in psychiatry2020
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.Eating and weight disorders : EWD · 2025Pooled it
- Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.Scientific reports · 2024Trial
- Increased global integration in the brain after psilocybin therapy for depression.Nature medicine · 2022Trial
- Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.Psychopharmacology · 2021Trial
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- Exploring the benefits of altered states of consciousness and reduced experiential avoidance for mental well-being: insights from a global study on high ventilation breathwork.Frontiers in psychology · 2026Article
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- Article
- Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.Journal of eating disorders · 2025Article
- The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses.Translational psychiatry · 2025Article
- Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.Psychopharmacology · 2025Article
- Psychedelics and Suicide-Related Outcomes: A Systematic Review.Journal of clinical medicine · 2025Review
- From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).Scientific reports · 2025Article
- Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.Frontiers in psychology · 2025Article
- Article
- Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.Frontiers in psychiatry · 2025Article
- Article
- Psychedelic-assisted psychotherapy: where is the psychotherapy research?Psychopharmacology · 2024Review
- Experiential Avoidance Process Model: A Review of the Mechanism for the Generation and Maintenance of Avoidance Behavior.Psychiatry and clinical psychopharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic therapy shows promise as a novel intervention for a wide range of mental health concerns but its therapeutic action is incompletely understood. In line with acceptance and commitment therapy's (ACT's) transdiagnostic model, qualitative research has suggested that reductions in experiential avoidance are an important component of therapeutic outcomes associated with psychedelics. However, limited research has quantitatively explored the association between decreases in experiential avoidance and therapeutic outcomes associated with psychedelics. Therefore, in two prospective studies, using convenience samples of individuals with plans to use a psychedelic, we explored the impact of psychedelic use on experiential avoidance, depression severity, and suicidal ideation, as well as relationships between changes in these outcomes. Participants (Study 1,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.